Thousand Oaks Biopharmaceuticals

A developer of biopharmaceutical technologies intended to produce protein and vaccine compounds.

Launch date

2017

Employees

Market cap

Enterprise valuation

Shantou Guangdong (HQ)

Date	Investors	Amount	Round
Jan 2017	N/A	N/A	Angel
Jan 2019*	BlueBay Asset Management Addor Capital New Alliance Capital Binghong Capital	$45.0m	Series A
Jul 2020	CICC Goldstone Investment Gold Stone Investment	$64.0m	Series B
Mar 2021	GL Ventures Capital Venture Investment Fund	$61.0m Valuation: $320m	Series C
Dec 2021*	CDH Investments Hillhouse Capital Goldstone Investment Highlight Capital	$235m	Series D
Jul 2022*	Timesbole	N/A	-
Total Funding		AUD626m

Recent News about Thousand Oaks Biopharmaceuticals